PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Gilbert, Mark R.
TI  - No Survival Advantage to Using Bevacizumab as First-Line Therapy for Glioblastoma
DP  - 2013 Aug 01
TA  - MD Conference Express
PG  - 10--11
VI  - 13
IP  - 6
4099  - http://mdc.sagepub.com/content/13/6/10.short
4100  - http://mdc.sagepub.com/content/13/6/10.full
AB  - Data from a Phase 3 study indicate that the use of bevacizumab (BEV) in glioblastoma should not be extended to the first-line setting. Currently, BEV is approved by the United States Food and Drug Administration for the treatment of recurrent glioblastoma. This article discusses findings from the double-blind, placebo-controlled, randomized trial entitled Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma [RTOG 0825; NCT00884741; Gilbert MR et al. J Clin Oncol 2013 (suppl; abstr 1)].